REG - Eden Research plc - Result of GM and Capital Raising update

Eden ResearchAnnouncement

17/08/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230817:nRSQ6395Ja&default-theme=true

RNS Number : 6395J  Eden Research plc  17 August 2023

17 August 2023

 

 

Eden Research

("Eden" or "the Company")

 

Result of General Meeting and Capital Raising update

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable
biopesticides and plastic-free formulation technology for use in the global
crop protection, animal health and consumer products industries, is pleased to
announce that all resolutions put forward to shareholders at the Company's
General Meeting held earlier today were duly passed.

 

The total number of votes received by proxy on each resolution, as more fully
disclosed in the Notice of Meeting available on the Company's website, was as
follows:

 

 #  Resolution                                                     For          %      Against  %     Withheld
 1  Grant authority to the Directors to allot Ordinary Shares      129,273,794  99.79  269,322  0.21  13,950
 2  Disapply statutory pre-emption rights on allotment of shares*  129,183,794  99.72  359,322  0.28  13,950
 3  Grant authority to cancel share premium account*               129,157,112  99.76  316,252  0.24  83,702

 

Notes:

·    * Denotes a Special Resolution.

·    A vote Withheld is not a vote in law and is not counted in the
calculation of the votes cast For or Against the resolution, nor in the
calculation of the percentage of issued share capital voted for any
resolution.

·    Votes For and Against are expressed as a percentage of votes validly
cast for that resolution by proxy, excluding any Withheld votes.

 

 

Capital Raising update

 

In the announcement made by the Company on 28 July 2023 regarding its Capital
Raising, it was stated that "The Placing of the Conditional Placing Shares is
conditional, inter alia, on (i) the approval of the Resolutions at the General
Meeting, (ii) the Advanced Assurance being obtained from HMRC, (iii) the
Capital Reduction becoming effective and (iv) Second Admission."

 

In addition to the Resolutions having been approved at the General Meeting
today, the Company is pleased to confirm that it has also obtained the
Advanced Assurance from HMRC required for the Conditional Placing.

 

The expected timetable for the satisfying the remaining conditions of the
Conditional Placing is as follows:

 

 Expected date for final hearing and confirmation of the Capital Reduction by  12 September
 the Court
 Expected date that the Capital Reduction become effective                     14 September
 Second Admission                                                              Expected second half of September
 Second Admission Long Stop Date                                               8 a.m. on 20 October

 

 

 

 
 

 

 

 

 

For further information contact:

 

 Eden Research plc                                     www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                            01285 359 555

Alex Abrey

 Cenkos Securities plc (Nominated advisor and broker)
 Giles Balleny / Max Gould (corporate finance)         020 7397 8900

Michael Johnson (sales)

 Hawthorn Advisors (Financial PR)
 Simon Woods                                           eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 Felix Meston

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMGIGDIUDBDGXR